Luminal B (HER–2 negative) breast cancer has poor sensitivity to neoadjuvant therapy, with a pCR rate of 5–10%, and the predictive value of pCR for long–term prognosis is not as high as that for HER–2 positive breast cancer and TNBC. This evidence concerns the gene ERBB2 and breast cancer.